All News
Immunogenicity makes a difference for mAbs like TNF inhibitors.
from Bart van den Bemt #EULAR2021 @RheumNow https://t.co/38ImlXdwUp
David Liew drdavidliew ( View Tweet)
So where might mAb therapeutic drug monitoring have the most value for us, going forward?
Proactive testing not at the moment (e.g. NOR-DRUM-A) but plenty of opportunities still exist!
6/
@MeghnaJani #EULAR2021 @RheumNow https://t.co/W5JATFHLfx
David Liew drdavidliew ( View Tweet)
So what might therapeutic drug monitoring (TDM) be able to do for you?
1/
@MeghnaJani #EULAR2021 @RheumNow https://t.co/f6x4JAE5pQ
David Liew drdavidliew ( View Tweet)
oh wait!
no photos, but NOR-DRUM B results:
Proactive TDM for dose optimisation during infliximab maintenance
- proportion pts w/o dx worsening: TDM better by 15%
- flare risk 2x with standard care vs TDM
- benefit across diseases (incl RA) & subgroups
Wow.
#EULAR2021 @RheumNow https://t.co/nTAuKE2ZJa
David Liew drdavidliew ( View Tweet)
Prof. Alten outlined the value of patient-reported outcomes for clinical practice!
How do you collect patient-reported outcomes - PRO - in your rheumatology clinic?
#EULAR2021 @RheumNow
Paul Studenic Stiddyo ( View Tweet)
#OP0145 Using a mixture of > 300 individuals with RA PsA or healthy the analyses via neural networks of HR-pQCT can differentiate the diagnosis assessing the bone surface with an accuracy of
89% #EULAR2021 @RheumNow
Paul Studenic Stiddyo ( View Tweet)
#OP0146 explores #US biomarkers in #at-risk RA individuals:
Tenosynovitis shows a HR of 2.9 to predict arthritis development - 57% of those with tenosynovitis developed arthritis vs 23% without
#EULAR2021 @RheumNow https://t.co/SPkzQqQ0e5
Paul Studenic Stiddyo ( View Tweet)
#OP0117 explores differences of TNFi or non-TNFi use on disease activity in a diverse population of the RISE register:
Black and Asian #RA patients greater reduction of #CDAI in non-TNFi
#EULAR2021 @RheumNow
Paul Studenic Stiddyo ( View Tweet)
#OP0127 A post-hoc analysis of two RCTs showed that continued
methotrexate increases clinical response rates in patients randomized to
placebo therapy who were considered as having previous insufficient response
to #bDMARDs. #EULAR2021 @RheumNow https://t.co/YeEVe0uwQs
Paul Studenic Stiddyo ( View Tweet)
Wednesday afternoon = @eular_org recommendations. @alessia_alunno presented EULAR PtC on COVID-19 pathophysiology and immunomodulatory therapies from the Rheumatology Perspective
Bottom Line: Proven efficacy in severe COVID-19 based on RCTs only dexamethason #EULAR2021 @RheumNow https://t.co/didtYEEWmq
Paul Studenic Stiddyo ( View Tweet)
Looking forward to the discussions in these sessions. #EULAR2021 https://t.co/GPLf4LbXLP
Paul Studenic Stiddyo ( View Tweet)
#OP0210
Analyses of RA patients using SRQ, DANBIO and national maternal registers: extensive anti-rheumatic treatment before and maternal disease activity during pregnancy associated with higher risk of pre term birth and small gestational age
#EULAR2021 @RheumNow https://t.co/qEniF4RC0l
Paul Studenic Stiddyo ( View Tweet)
#OP0229 GRAPPA recommendations crisply presented by @DrLauraCoates
Importantly it needs to be tailored to the patient taking amongst under comorbidities and the heterogeneity of features of the clinical presentation into account.
#EULAR2021 @RheumNow https://t.co/MpZGzhq0Ic
Paul Studenic Stiddyo ( View Tweet)
#OP0231 BADBIR register (incl. Ustekinumab & csDMARD treated patients) 2697 PsO without PsA & 590 PsO with PsA:
obesity, diabetes, hypetension and inabililty to work was more likely in Pso patients with PsA than patients with PsO alone
#EULAR2021 @RheumNow
Paul Studenic Stiddyo ( View Tweet)
#OP0233 In SELECT-PsA1 & 2 analyses for PsA with axial involvement: 31% / 34% of the studies population:
> Improvement of axial symptoms on upadacitinib across several outcomes compared to PLC!
> 1new onset of uveitis on upadacitinib
#EULAR2021
@RheumNow https://t.co/9YK1OYEorq
Paul Studenic Stiddyo ( View Tweet)
Dr. Gladman highlighted the full spectrum of #PsA in today's #EULAR2021 afternoon session.
"-> All domains need to be assessed in our psa patients!
-> Its interesting that we have not been able to identify genetic dispositions to particular features "
@RheumNow
Paul Studenic Stiddyo ( View Tweet)
Does clinical response equate good #HRQoL in #SLE? Dr Gomez analysed responders in #belimumab trials and showed up to 29% pts reported poor SF-36 (esp physical aspects). Physical functioning & fatigue improved with therapy #EULAR2021 #POS0101 @RheumNow https://t.co/IU1k0UetEx
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Is there a need to routinely monitor #ANA in patients treated on #TNF inhibitors? The jury👨⚖️is still out. Of N=211, Dr Oliveira reported 75.4% had seroconversion at median 31mths of TNFi therapy. Only 2/211 (0.9%) developed SLE (mild symptoms) #EULAR2021 #POS0204 @RheumNow https://t.co/UrFucJ9xnJ
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#MachineLearning to unravel pathways associated with #SLE. Dr Morand analysed N=1760 pts from RCTs. Using deep learning algorithms, they identified novel pathways (CD4 Tcell Differentiation, Macrophage and DCs) in addition to known #IFN and #JAKSTAT #EULAR2021 #POS0351 @RheumNow https://t.co/Gc7zL8JQZe
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#Interferon as biomarkers in #RMD? Dr Burska on behalf of #EULAR TF reported heterogeneity in published papers re:IFN-I pathway activation assays, hence unable to perform meta-analyses of results.They proposed Consensus Terminology for IFN #research #EULAR2021 #POS0370 @RheumNow https://t.co/lbqy2xbEyt
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
